COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics

Amawi, H; Abu Deiab, GI; A Aljabali, AA; Dua, K; Tambuwala, MM

COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics

Amawi, H Abu Deiab, GI A Aljabali, AA Dua, K

Tambuwala, MM

Permalink

Publisher:: Future Science Ltd
Publication Type:: Journal Article
Citation:: Therapeutic Delivery, 2020, 11, (4), pp. 245-268
Issue Date:: 2020-04

Closed Access

	Filename	Description	Size
	tde-2020-0035.pdf	Published version	3.95 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Amawi, H
dc.contributor.author	Abu Deiab, GI
dc.contributor.author	A Aljabali, AA
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Tambuwala, MM
dc.date.accessioned	2020-05-21T23:00:59Z
dc.date.available	2020-05-21T23:00:59Z
dc.date.issued	2020-04
dc.identifier.citation	Therapeutic Delivery, 2020, 11, (4), pp. 245-268
dc.identifier.issn	2041-5990
dc.identifier.issn	2041-6008
dc.identifier.uri	http://hdl.handle.net/10453/140874
dc.description.abstract	<jats:p> At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA-approved drugs as there is no available vaccine yet with many attempts under clinical evaluation. Several antivirals, antimalarials and immunomodulators that have shown activity against SARS-CoV and Middle East coronavirus respiratory syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results. The main aim of this review is to provide an overview of this pandemic and where we currently stand. </jats:p>
dc.language	en
dc.publisher	Future Science Ltd
dc.relation.ispartof	Therapeutic Delivery
dc.relation.isbasedon	10.4155/tde-2020-0035
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	0903 Biomedical Engineering, 1004 Medical Biotechnology, 1115 Pharmacology and Pharmaceutical Sciences
dc.title	COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics
dc.type	Journal Article
utslib.citation.volume	11
utslib.for	0903 Biomedical Engineering
utslib.for	1004 Medical Biotechnology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	closed_access	*
dc.date.updated	2020-05-21T23:00:53Z
pubs.issue	4
pubs.publication-status	Published
pubs.volume	11
utslib.start-page	245
utslib.citation.issue	4

Abstract:

At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA-approved drugs as there is no available vaccine yet with many attempts under clinical evaluation. Several antivirals, antimalarials and immunomodulators that have shown activity against SARS-CoV and Middle East coronavirus respiratory syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results. The main aim of this review is to provide an overview of this pandemic and where we currently stand.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/140874